Vision :  Reduce health inequities by expanding patient access to therapeutic biologics. 

 

Our oral biologics for gastrointestinal (GI) disorders will:

1. Improve patient accessibility to biologics with at home, non-refrigerated, convenient oral capsules

2.  Improve patient compliance with no needles and no  health-care administrated infusion

3.  Improve chronic use outcomes given the high safety profile, no ADA, no systemic toxicity​

​​

The Fzata proprietary oral Bioengineered Probiotic Yeast Medicines (BioPYM) uses yeast micro-factories to make biologic therapeutics “on-site” in the gut for treatment of GI diseases.  

BioPYM has generated a deep pipeline of oral biologics for GI-related disorders.

​

​